Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Ipsen acquires Kartos Therapeutics for oncology boost

PRIVATEAug 21, 2026•about 4 hours ago

Acquiring Company

Ipsen

Acquired Company

Kartos Therapeutics

Professional ServicesBiotechnologyHealth CareTherapeutics

Description

Ipsen has successfully completed the acquisition of Kartos Therapeutics. This move is aimed at strengthening Ipsen's late-stage oncology pipeline. The integration of Kartos will enhance Ipsen’s capabilities in cancer treatment. The details of the acquisition have not been disclosed.

Company Information

Company

Ipsen

About

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Tazverik® is a registered trademark of Epizyme.

Don't miss Ipsen's next move

Get an email the moment Ipsen makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Simone
Senior decision-maker at this company
••••••••@••••••••

See Simone's verified email →

Diana
Senior decision-maker at this company
••••••••@••••••••

See Diana's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Ipsen's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Kartos Therapeutics?

Kartos Therapeutics was acquired by Ipsen. The deal was reported on August 21, 2026. Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. Ipsen is privately held and operates in Professional Services.

When did Ipsen acquire Kartos Therapeutics?

Ipsen's acquisition of Kartos Therapeutics was reported on August 21, 2026. Ipsen has successfully completed the acquisition of Kartos Therapeutics. This move is aimed at strengthening Ipsen's late-stage oncology pipeline. The integration of Kartos will enhance Ipsen’s capabilities in cancer treatment. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Kartos Therapeutics do?

Kartos Therapeutics is a biotechnology company specializing in the development of innovative cancer therapies. The company aims to provide effective treatment options for patients with severe unmet medical needs. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.